CSIMarket
 


Regenerx Biopharmaceuticals inc   (RGRX)
Other Ticker:  
 

Regenerx Biopharmaceuticals Inc 's Quick Ratio

RGRX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the first quarter 2023, Quick Ratio fell to 0.06 below Regenerx Biopharmaceuticals Inc average.

Within Major Pharmaceutical Preparations industry 473 other companies have achieved higher Quick Ratio than Regenerx Biopharmaceuticals Inc in first quarter 2023. While Quick Ratio total ranking in the first quarter 2023 has deteriorated compared to the prior quarter from 2734 to 3808.

Explain Quick Ratio?
How much Cash & cash equivalents RGRX´s has?
What are RGRX´s Current Liabilities?


RGRX Quick Ratio (Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
Y / Y Current Liabilities Change 346.55 % 28.8 % 14.06 % -31.61 % -6.65 %
Y / Y Cash & cash equivalent Change -89.02 % -76.38 % -68.6 % -65.11 % 345.68 %
Quick Ratio MRQ 0.06 0.53 1 1.63 2.3
RGRX's Total Ranking # 3808 # 2734 # 2003 # 2029 # 1199
Seq. Current Liabilities Change 225.01 % 16.27 % 10 % 7.42 % -6.26 %
Seq. Cash & cash equivalent Change -65.09 % -39.2 % -32.3 % -23.63 % -24.87 %



Quick Ratio first quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 474
Healthcare Sector # 962
Overall Market # 3808


Quick Ratio Statistics
High Average Low
5.95 1.44 0.01
(Jun 30 2019)   (Jun 30 2013)




Financial Statements
Regenerx Biopharmaceuticals Inc 's Current Liabilities $ 2 Millions Visit RGRX's Balance sheet
Regenerx Biopharmaceuticals Inc 's Cash & cash equivalent $ 0 Millions Visit RGRX's Balance sheet
Source of RGRX's Sales Visit RGRX's Sales by Geography


Cumulative Regenerx Biopharmaceuticals Inc 's Quick Ratio

RGRX's Quick Ratio for the trailling 12 Months

RGRX Quick Ratio

(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
Y / Y Current Liabilities TTM Growth 346.55 % 28.8 % 14.06 % -31.61 % -6.65 %
Y / Y Cash & cash equivalent TTM Growth -89.02 % -76.38 % -68.6 % -65.11 % 345.68 %
Quick Ratio TTM 0.48 1.29 1.92 2.61 3.03
Total Ranking TTM # 2310 # 1760 # 1421 # 1382 # 1330
Seq. Current Liabilities TTM Growth 225.01 % 16.27 % 10 % 7.42 % -6.26 %
Seq. Cash & cash equivalent TTM Growth -65.09 % -39.2 % -32.3 % -23.63 % -24.87 %


On the trailing twelve months basis Due to in Current Liabilities in the I Quarter 2023 to $1.80 millions, cumulative Quick Ratio decreased to 0.48 below the Regenerx Biopharmaceuticals Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 555 other companies have achieved higher Quick Ratio than Regenerx Biopharmaceuticals Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the forth quarter 2022 from 2218 to 3772.

Explain Quick Ratio?
How much Cash & cash equivalents RGRX´s has?
What are RGRX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 556
Healthcare Sector # 1125
Within the Market # 3808


trailing twelve months Quick Ratio Statistics
High Average Low
3.58 1.61 0.26
(Dec 31 2019)   (Dec 31 2017)




Companies with similar Quick Ratio in the quarter ending Mar 31 2023, within Major Pharmaceutical Preparations Industry Quick RatioMar 31 2023 MRQ Cash & cash equivalentMar 31 2023 MRQ Current Liabilities
Zyversa Therapeutics Inc   0.15 $ 1.325  Millions$ 8.578  Millions
Accustem Sciences Inc   0.15 $ 0.181  Millions$ 1.194  Millions
Scopus Biopharma Inc   0.15 $ 1.401  Millions$ 9.313  Millions
Northwest Biotherapeutics inc  0.14 $ 6.191  Millions$ 44.708  Millions
Bausch Health Companies Inc   0.13 $ 518.000  Millions$ 3,923.000  Millions
Protokinetix Incorporated  0.13 $ 0.007  Millions$ 0.053  Millions
Celularity Inc   0.13 $ 8.532  Millions$ 66.458  Millions
Takeda Pharmaceutical Company Limited  0.12 $ 3,919.815  Millions$ 31,529.984  Millions
Cv Sciences Inc   0.11 $ 0.714  Millions$ 6.253  Millions
Innovation1 Biotech Inc   0.11 $ 0.262  Millions$ 2.335  Millions
Nascent Biotech Inc  0.11 $ 0.172  Millions$ 1.551  Millions
Janone Inc   0.10 $ 0.353  Millions$ 3.477  Millions
Dr Reddy s Laboratories Limited  0.10 $ 103.000  Millions$ 1,044.000  Millions
China Pharma Holdings Inc   0.10 $ 1.167  Millions$ 11.922  Millions
Cytodyn inc   0.09 $ 11.110  Millions$ 121.334  Millions
Viatris Inc   0.08 $ 506.600  Millions$ 6,108.100  Millions
Supernus Pharmaceuticals inc   0.08 $ 58.442  Millions$ 731.545  Millions
Athersys Inc  0.08 $ 3.121  Millions$ 39.683  Millions
Aeon Biopharma inc   0.08 $ 0.457  Millions$ 5.873  Millions
Nabriva Therapeutics Plc  0.06 $ 1.798  Millions$ 27.998  Millions
Lannett Company Inc  0.06 $ 46.540  Millions$ 733.079  Millions
American Bio Medica Corporation  0.06 $ 0.068  Millions$ 1.117  Millions
Humanigen Inc  0.06 $ 3.096  Millions$ 53.296  Millions
Regenerx Biopharmaceuticals inc   0.06 $ 0.102  Millions$ 1.800  Millions
Aditxt Inc   0.05 $ 0.303  Millions$ 5.910  Millions
Neptune Wellness Solutions Inc   0.05 $ 2.011  Millions$ 41.034  Millions
Conduit Pharmaceuticals Inc   0.05 $ 0.091  Millions$ 1.958  Millions
One World Products Inc   0.04 $ 0.135  Millions$ 3.118  Millions
Gelesis Holdings Inc   0.04 $ 3.103  Millions$ 76.185  Millions
Aridis Pharmaceuticals Inc   0.04 $ 1.320  Millions$ 35.431  Millions

Date modified: 2023-05-17T01:10:57+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com